BioCentury | Jan 5, 2015
Clinical News

Nebivolol/valsartan regulatory update

...generic small molecule angiotensin II receptor (type AT1) antagonist. Actavis plc (NYSE:ACT), Dublin, Ireland Product: Nebivolol/valsartan...
BioCentury | Sep 15, 2014
Clinical News

Nebivolol/valsartan regulatory update

...whether the combo provides a "clinically meaningful" benefit in patients with hypertension. Actavis gained the nebivolol/valsartan...
...generic small molecule angiotensin II receptor (type AT1) antagonist. Actavis plc (NYSE:ACT), Dublin, Ireland Product: Nebivolol/valsartan...
BioCentury | Sep 11, 2014
Company News

FDA panel rebuffs Actavis' nebivolol/valsartan

...in patients with hypertension (see BioCentury Extra, Sept. 5) . Actavis -- which gained the nebivolol/valsartan...
BioCentury | Sep 6, 2014
Company News

FDA reviewers question nebivolol/valsartan benefit

..."too small to be useful." The reviewers did note that the highest dose of the nebivolol/valsartan...
BioCentury | Mar 3, 2014
Clinical News

Nebivolol/valsartan regulatory update

...molecule angiotensin II receptor (type AT1) antagonist. Forest Laboratories Inc. (NYSE:FRX), New York, N.Y. Product: Nebivolol/valsartan...
Items per page:
1 - 5 of 5